Celia Oreja-Guevara
Celia Oreja-Guevara
Neurology Hospital Clinico San Carlos, Assoc. Professor Universidad Complutense Madrid
Verified email at ucm.es
Cited by
Cited by
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
Clinical relevance of brain volume measures in multiple sclerosis
N De Stefano, L Airas, N Grigoriadis, HP Mattle, J O’Riordan, ...
CNS drugs 28 (2), 147-156, 2014
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis
A Petzold, LJ Balcer, PA Calabresi, F Costello, TC Frohman, EM Frohman, ...
The Lancet Neurology 16 (10), 797-812, 2017
Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study
EH Martinez-Lapiscina, S Arnow, JA Wilson, S Saidha, JL Preiningerova, ...
The Lancet Neurology 15 (6), 574-584, 2016
Geographical variations in sex ratio trends over time in multiple sclerosis
M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ...
PLOS one 7 (10), e48078, 2012
Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings
AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ...
Neurology 89 (11), 1117-1126, 2017
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy
E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ...
Neurology 89 (11), 1107-1116, 2017
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open …
R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ...
The Lancet Neurology 17 (5), 405-415, 2018
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ...
Annals of neurology 77 (3), 425-435, 2015
Predictors and dynamics of postpartum relapses in women with multiple sclerosis
SE Hughes, T Spelman, OM Gray, C Boz, M Trojano, A Lugaresi, ...
Multiple Sclerosis Journal 20 (6), 739-746, 2014
Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study
C Oreja-Guevara, M Rovaris, G Iannucci, P Valsasina, D Caputo, ...
Archives of Neurology 62 (4), 578-584, 2005
Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis
J Rivera-Navarro, J Benito-León, C Oreja-Guevara, J Pardo, ...
Multiple Sclerosis Journal 15 (11), 1347-1355, 2009
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
T Kalincik, V Vivek, V Jokubaitis, J Lechner-Scott, M Trojano, G Izquierdo, ...
Brain 136 (12), 3609-3617, 2013
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
C Oreja-Guevara, J Ramos-Cejudo, LS Aroeira, B Chamorro, ...
BMC neurology 12 (1), 1-6, 2012
Defining reliable disability outcomes in multiple sclerosis
T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ...
Brain 138 (11), 3287-3298, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis
A He, T Spelman, V Jokubaitis, E Havrdova, D Horakova, M Trojano, ...
JAMA neurology 72 (4), 405-413, 2015
Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus
M Sepúlveda, T Armangué, N Sola-Valls, G Arrambide, JE Meca-Lallana, ...
Neurology-Neuroimmunology Neuroinflammation 3 (3), 2016
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice
JCC de Sa, L Airas, E Bartholome, N Grigoriadis, H Mattle, ...
Therapeutic advances in neurological disorders 4 (3), 139-168, 2011
Therapeutic decisions in multiple sclerosis: moving beyond efficacy
W Brück, R Gold, BT Lund, C Oreja-Guevara, A Prat, CM Spencer, ...
JAMA neurology 70 (10), 1315-1324, 2013
The system can't perform the operation now. Try again later.
Articles 1–20